Nanoparticles & Alzheimer’s: Diagnosis & New Therapies

Dementia is no longer a looming crisis; it’s a present reality, now the leading cause of death in Australia. But a new frontier in the fight against Alzheimer’s disease – the most prevalent form of dementia – is emerging, leveraging the power of nanotechnology and a revolutionary imaging technique called Magnetic Particle Imaging (MPI). This isn’t just incremental progress; it represents a potential paradigm shift in how we diagnose, monitor, and ultimately treat this devastating disease.

For over a century, since Alois Alzheimer first described the disease in 1906, our understanding of Alzheimer’s has centered on the accumulation of amyloid-beta plaques and tau tangles. While these remain key pathological hallmarks, translating that understanding into effective treatments has proven incredibly challenging. The blood-brain barrier (BBB), a protective mechanism preventing harmful substances from entering the brain, has been a particularly stubborn obstacle. Traditional drug delivery methods struggle to effectively cross this barrier, limiting the therapeutic impact.

Nanotechnology offers a potential solution. The unique properties of nanoparticles – their small size, high surface area, and modifiable chemistry – allow them to be engineered to overcome the BBB and deliver targeted therapies directly to affected brain regions. However, early attempts at nanoparticle-based therapies faced hurdles, including difficulties in accurately tracking their distribution within the body and unintended biological interactions, like the “protein corona effect” where proteins in the bloodstream coat the nanoparticles, altering their behavior.

This is where Magnetic Particle Imaging (MPI) enters the picture. Developed in the early 2000s, MPI provides a direct, quantifiable signal from magnetic nanoparticles, unlike MRI which relies on indirect measurements. This breakthrough allows researchers to precisely track nanoparticle movement, monitor drug delivery, and map disease progression with unprecedented accuracy. The ability to combine MPI with therapeutic nanoparticles – like curcumin conjugated to magnetic particles for anti-inflammatory action – represents a significant leap towards true precision medicine in neurodegenerative disease.

The Forward Look

The establishment of MPI systems at institutions like UNSW’s Centre for Healthy Brain Ageing (CHeBA) is a critical step, but several key developments will determine the future of this field. Firstly, further research is needed to refine nanoparticle design to minimize the protein corona effect and maximize targeting efficiency. Secondly, the scalability and cost-effectiveness of MPI technology need to be addressed to facilitate wider adoption. The potential for portable, bedside MPI systems is particularly exciting, promising earlier and more accessible diagnosis.

Looking ahead, we can anticipate a surge in clinical trials utilizing MPI-guided nanotherapies for Alzheimer’s disease. The success of these trials will hinge on demonstrating not only safety and efficacy but also the ability to detect meaningful changes in disease progression. Beyond Alzheimer’s, the principles of MPI and nanomedicine could be applied to other neurodegenerative diseases, such as Parkinson’s and Huntington’s. Australia, with its emerging leadership in this area, has a significant opportunity to become a global hub for innovation in neuroimaging and nanotherapeutics, offering hope to the millions worldwide affected by these debilitating conditions. The convergence of these technologies isn’t just a scientific advancement; it’s a crucial investment in the future of brain health.

Dr Saeed Shanehsazzadeh is a Research Associate at CHeBA. He holds a PhD in Medical Physics from Tehran University of Medical Sciences and has over a decade of experience in molecular imaging, nanomedicine, and multidisciplinary medical sciences labs in Iran, Germany, Belgium, Canada, Singapore and Australia. His work focuses on advancing magnetic particle imaging (MPI) as a novel method for detecting early changes in the brain related to neurodegenerative diseases.

Professor Perminder Sachdev AM is a Scientia Professor of Neuropsychiatry and Co-Director of the Centre for Healthy Brain Ageing (CHeBA) in the Discipline of Psychiatry and Mental Health at the University of New South Wales (UNSW Sydney), with research and clinical interests including neuropsychiatric disorders of older people and disorders of cognition, vascular dementia, Alzheimer’s disease, dementia of Lewy Body type, and Mild Cognitive Impairment. He is also Clinical Director of the Neuropsychiatric Institute (NPI) at the Prince of Wales Hospital and Deputy Chair of the Australian Dementia Network (ADNeT).  

The statements or opinions expressed in this article reflect the views of the authors and do not necessarily represent the official policy of the AMA, the MJA or InSight+ unless so stated. 

Subscribe to the free InSight+ weekly newsletter here. It is available to all readers, not just registered medical practitioners. 

If you would like to submit an article for consideration, send a Word version to [email protected].